Madrigal Pharmaceuticals, Inc. (MDGL)
NASDAQ: MDGL · Real-Time Price · USD
512.65
-1.14 (-0.22%)
At close: Jun 26, 2026, 4:00 PM EDT
512.00
-0.65 (-0.13%)
After-hours: Jun 26, 2026, 4:48 PM EDT
Madrigal Pharmaceuticals Employees
Madrigal Pharmaceuticals had 915 employees as of December 31, 2025. The number of employees increased by 387 or 73.30% compared to the previous year.
Employees
915
Change (1Y)
387
Growth (1Y)
73.30%
Revenue / Employee
$1,237,694
Profits / Employee
-$338,183
Market Cap
11.82B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| BioMarin Pharmaceutical | 3,221 |
| Bio-Techne | 3,100 |
| Ionis Pharmaceuticals | 1,402 |
| Axsome Therapeutics | 1,220 |
| Exelixis | 1,077 |
| BridgeBio Pharma | 839 |
| Arrowhead Pharmaceuticals | 711 |
| Cytokinetics | 673 |
MDGL News
- 5 days ago - Madrigal Pharmaceuticals Announces Grants of Inducement Awards under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 10 days ago - Madrigal Pharmaceuticals management to meet with Piper Sandler - TheFly
- 16 days ago - Madrigal Pharmaceuticals price target lowered to $542 from $550 at BofA - TheFly
- 17 days ago - Madrigal Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026 - Transcripts
- 24 days ago - Madrigal Pharmaceuticals to Participate in the 47th Annual Global Goldman Sachs Health Care Conference 2026 - GlobeNewsWire
- 4 weeks ago - Madrigal Pharmaceuticals announces new analyses of Rezdiffra data - TheFly
- 4 weeks ago - Madrigal Presents Data Demonstrating Rezdiffra Reduced Markers of Cardiovascular and Liver-Related Risk in Patients with MASH - GlobeNewsWire
- 5 weeks ago - Madrigal to Present New Data from the Company's MASH Program at EASL 2026 Demonstrating the Effects of Rezdiffra on Markers of Cardiovascular and Portal Hypertension Risk - GlobeNewsWire